Development of Graves' disease in a patient with lymphocytic hypophysitis following glucocorticoid treatment
- PMID: 40557834
- PMCID: PMC12207596
- DOI: 10.1530/EDM-24-0145
Development of Graves' disease in a patient with lymphocytic hypophysitis following glucocorticoid treatment
Abstract
Summary: We report the case of a 41-year-old Japanese woman with visual field disturbances during late pregnancy. At 39 weeks of gestation, she was diagnosed with bitemporal hemianopsia at the ophthalmology department. An MRI revealed a symmetrical pituitary gland enlargement, compressing the optic chiasm. An emergency cesarean section was performed immediately, resulting in the delivery of a male infant weighing 3,112 grams. Laboratory tests indicated low serum free thyroxine (T4), thyroid-stimulating hormone (TSH), cortisol, luteinizing hormone, and follicle-stimulating hormone. The patient was clinically diagnosed with lymphocytic hypophysitis (LHy). Due to her visual field impairment, she was administered 60 mg of prednisolone daily. After 2 days, her visual field impairment improved rapidly, leading to a gradual tapering of the dose. Six months after treatment initiation, an MRI showed shrinkage of the pituitary gland. Her prednisolone dose was reduced to 5 mg daily, and she was switched to hydrocortisone at 15 mg daily. Twelve months after starting treatment, the patient developed thyrotoxicosis. Testing revealed a positive TSH receptor antibody, resulting in a diagnosis of Graves' disease (GD). Treatment with thiamazole (15 mg daily) and potassium iodide (76 mg daily) was initiated, and her thyroid function normalized after 2 months. LHy is believed to have an autoimmune mechanism and is frequently associated with other autoimmune diseases; however, the development of GD is rare. Development of Graves' disease should be considered in patients with LHy, particularly during the postpartum period and the glucocorticoid treatment process.
Learning points: Females with lymphocytic hypophysitis often experience local symptoms, such as visual field disorders, when pregnant. This condition is frequently associated with autoimmune diseases, particularly autoimmune thyroid disorders. However, reports explicitly linking it to Graves' disease have been limited. The postpartum period is considered a trigger of the onset of Graves' disease. In addition, the high-dose glucocorticoid treatment and its tapering may affect it.
Keywords: Graves’ disease; glucocorticoids; lymphocytic hypophysitis; pregnancy.
Conflict of interest statement
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Figures

Similar articles
-
Pain management for medical abortion before 14 weeks' gestation.Cochrane Database Syst Rev. 2022 May 13;5(5):CD013525. doi: 10.1002/14651858.CD013525.pub2. Cochrane Database Syst Rev. 2022. PMID: 35553047 Free PMC article.
-
Radioiodine therapy versus antithyroid medications for Graves' disease.Cochrane Database Syst Rev. 2016 Feb 18;2(2):CD010094. doi: 10.1002/14651858.CD010094.pub2. Cochrane Database Syst Rev. 2016. PMID: 26891370 Free PMC article.
-
Unilateral Graves' disease: a case report with concomitant thyroid cancer and systematic review of literature.Minerva Surg. 2025 Jun;80(3):274-281. doi: 10.23736/S2724-5691.25.10685-0. Epub 2025 May 22. Minerva Surg. 2025. PMID: 40401585
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Corticosteroids for the treatment of Duchenne muscular dystrophy.Cochrane Database Syst Rev. 2016 May 5;2016(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Cochrane Database Syst Rev. 2016. PMID: 27149418 Free PMC article.
References
LinkOut - more resources
Full Text Sources